Irish heart drug developer Amarin Corp. PLC, with Stonington research operations, says it has been cleared for a patent on a key component of its proposed cardiovascular treatment.
Amarin said Tuesday the U.S. Patent and Trademark Office published a notice of allowance for its patent application serial No.12/052,598 titled "Highly Purified Ethyl EPA and Other EPA Derivatives," also known as the EPA with no DHA in a capsule application.
A notice of allowance is issued once the patent office determines that a patent can be granted from an application.
It is one of 16 pending U.S. patent applications for Amarin, the company says.
"The issuance of a notice of allowance is a significant additional step forward in the execution of our plan to protect the commercial potential of AMR101," Amarin Chairman and CEO Joseph Zakrzewski said in a statement.
Patent protection is crucial for drug developers like Amarin who use it to protect their trade secrets while they refine them for introduction into the marketplace.
Amarin also has filed with U.S. drug regulators for clearance to market an omega-3 fatty acid treatment to curb blood triglycerides harmful to the heart.
The company's domicile is Dublin, Ireland, but operational headquarters are with Zakrzewski in Bedminster, N.J.